Mohsen Paulash 4
4 · YUMANITY THERAPEUTICS, INC. · Filed Dec 28, 2020
Insider Transaction Report
Form 4
Mohsen Paulash
Chief Business Officer
Transactions
- Award
Stock Option (Right to Buy)
2020-12-22+42,168→ 42,168 totalExercise: $8.16Exp: 2028-12-03→ Common Stock (42,168 underlying) - Award
Common Stock
2020-12-22+36,428→ 36,428 total - Award
Stock Option (Right to Buy)
2020-12-22+10,542→ 10,542 totalExercise: $8.16Exp: 2030-02-17→ Common Stock (10,542 underlying)
Footnotes (6)
- [F1]On August 22, 2020, the Issuer (formerly known as Proteostasis Therapeutics, Inc.) entered into an Agreement and Plan of Merger and Reorganization, as amended on November 6, 2020, with Pangolin Merger Sub, Inc. ("Merger Sub"), Yumanity, Inc. (formerly known as Yumanity Therapeutics, Inc.) and Yumanity Holdings, LLC ("Holdings"). On December 22, 2020, Merger Sub was merged with and into Yumanity, Inc., with Yumanity, Inc. surviving as a wholly-owned subsidiary of the Issuer (the "Merger"). Immediately prior to the consummation of the Merger, Holdings was merged with and into Yumanity, Inc., with Yumanity, Inc. as the surviving entity.
- [F2]The shares were received in exchange for 172,776.09 shares of Yumanity, Inc. common stock in connection with the Merger.
- [F3]25% of the shares subject to the option vested on December 4, 2019. The remaining 75% vest in equal monthly installments over the subsequent three years.
- [F4]Received in the Merger in exchange for a stock option to acquire 200,000 shares of Yumanity, Inc. common stock for $1.72 per share.
- [F5]25% of the shares subject to the option vest on February 18, 2021. The remaining 75% vest in equal monthly installments over the subsequent three years.
- [F6]Received in the Merger in exchange for a stock option to acquire 50,000 shares of Yumanity, Inc. common stock for $1.72 per share.